BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lipitor atorvastatin: Postmarketing study data

Pfizer Inc. (NYSE:PFE), New York, N.Y.
Product: Lipitor atorvastatin
Business: Metabolic
Molecular target: HMG- CoA reductase
Description: HMG-CoA reductase inhibitor
Indication: Reduce blood cholesterol levels
Endpoint: Proportion of patients developing new-onset Type II diabetes
Status: Postmarketing study data
Milestone: NA
Researchers at Pfizer, the University of California, San Francisco, and colleagues reported...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >